In a review of recently published scientific studies, investigators at Keck School of Medicine of USC identified a natural barrier to the inner’s sensory cells’ ability to regenerate.
With a new wave of Covid-19 infections fueled by the Delta variant striking countries worldwide, disease experts are scrambling to learn whether the latest version of coronavirus is making people – mainly the unvaccinated – sicker than before.
AstraZeneca said a late-stage trial failed to provide evidence that the company’s Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.
The U.S. Centers for Disease Control and Prevention (CDC) on May 13 advised that fully vaccinated people do not need to wear masks outdoors and can avoid wearing them indoors in most places, updated guidance the agency said will allow life to begin to return to normal.
Topline results from an investigator-initiated trial in Brazil show that treatment with Kintor Pharmaceutical’s proxalutamide cut mortality risk by 92 percent and significantly shortened the median length of hospital stay by nine days compared with standard of care in hospitalized patients with coronavirus disease 2019.
The U.S. National Institutes of Health (NIH) halted a trial of convalescent blood plasma in the treatment of patients with mild-to-moderate Covid-19 symptoms as it was unlikely to benefit this group.
People who have received the full course of Covid-19 vaccines can skip the standard 14-day quarantine after exposure to someone with the infection as long as they remain asymptomatic, U.S. public health officials advised.
A roundup of scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes research on Covid-19 patients who still have symptoms 6 months after falling ill.
Blocking TNF production could offer a more effective solution for the treatment of COVID-19.
Using blood plasma from Covid-19 survivors to treat patients with severe pneumonia caused by the novel coronavirus showed little benefit, according to data released from a clinical trial in Argentina.